Treatment of Fatigue in Parkinson Disease.
OBJECTIVE
Which pharmacological and nonpharmacological interventions are associated with improvement in general, physical, or mental fatigue and minimal adverse effects in patients with Parkinson disease (PD)?


CONCLUSIONS
Rasagiline, modafinil, and doxepin are associated with improvement in fatigue and are not associated with increased risk of adverse effects in patients with PD. However, the quality of evidence is limited and does not provide a clear basis for treatment decisions.
Department of Physiotherapy, University of Applied Sciences, Leiden, the Netherlands2Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Roy G
RG
Elbers
Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.
Henk W
HW
Berendse
Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Gert
G
Kwakkel
D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D015444:Exercise; D005221:Fatigue / Q000628:therapy*; D006801:Humans; D010300:Parkinson Disease / Q000150:complications*
D000697:Central Nervous System Stimulants; D015259:Dopamine Agents